Indium-111 labelled pooled human immunoglobulin imaging to monitor the efficacy of specific therapy for Pneumocystis carinii pneumonia
Identifieur interne : 000183 ( Main/Exploration ); précédent : 000182; suivant : 000184Indium-111 labelled pooled human immunoglobulin imaging to monitor the efficacy of specific therapy for Pneumocystis carinii pneumonia
Auteurs : RBID : ISTEX:259_1994_Article_BF00181072.pdfDescripteurs français
- Wicri :
- topic : Sida.
English descriptors
Abstract
Functional imaging is ideally suited to monitoring the effect of specific therapy on disease processes. In this pilot study five patients with AIDS and Pneumocystis carinii pneumonia (PCP) were imaged with Indium-111 labelled pooled human immunoglobulin (111In-HIG) during infection and after therapy for PCP. The lung activity of t t tln-HIG, measured as a lung/heart ratio, was calculated in a study performed during infection with PCP and after therapy. In all five patients the lung/heart ratio of t t 1ln-HIG was reduced after treatment. The mean reduction in heart/lung ratio was 27% (range 12%-53%). If these results are confirmed by a larger study, 11In-HIG will be useful in monitoring the response of PCP to therapy in patients with AIDS.
DOI: 10.1007/BF00181072
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Indium-111 labelled pooled human immunoglobulin imaging to monitor the efficacy of specific therapy for Pneumocystis carinii pneumonia</title><author><name>J. R. Buscombe</name><affiliation wicri:level="1"><mods:affiliation>Royal Free Hospital and School of Medicine, London, UK</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Free Hospital and School of Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name>I. Khalkhali</name><affiliation wicri:level="1"><mods:affiliation>Harbor-UCLA Medical Centre, Torrance, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harbor-UCLA Medical Centre, Torrance, California</wicri:regionArea><wicri:noRegion>California</wicri:noRegion></affiliation></author><author><name>G. R. Mason</name><affiliation wicri:level="1"><mods:affiliation>Harbor-UCLA Medical Centre, Torrance, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harbor-UCLA Medical Centre, Torrance, California</wicri:regionArea><wicri:noRegion>California</wicri:noRegion></affiliation></author><author><name>D. Rauh</name><affiliation wicri:level="1"><mods:affiliation>R.W. Johnson Pharmaceutical Research Institute, Spring House, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>R.W. Johnson Pharmaceutical Research Institute, Spring House</wicri:regionArea><wicri:noRegion>Spring House</wicri:noRegion></affiliation></author><author><name>J. Meatherall</name><affiliation wicri:level="1"><mods:affiliation>R.W. Johnson Pharmaceutical Research Institute, Spring House, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>R.W. Johnson Pharmaceutical Research Institute, Spring House</wicri:regionArea><wicri:noRegion>Spring House</wicri:noRegion></affiliation></author><author><name>W. J. G. Oyen</name><affiliation wicri:level="1"><mods:affiliation>University Hospital, Nijmegen, Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>University Hospital, Nijmegen</wicri:regionArea><wicri:noRegion>Nijmegen</wicri:noRegion></affiliation></author><author><name>F. H. M. Corstens</name><affiliation wicri:level="1"><mods:affiliation>University Hospital, Nijmegen, Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>University Hospital, Nijmegen</wicri:regionArea><wicri:noRegion>Nijmegen</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1994_Article_BF00181072.pdf</idno><date when="1994">1994</date><idno type="doi">10.1007/BF00181072</idno><idno type="wicri:Area/Main/Corpus">000213</idno><idno type="wicri:Area/Main/Curation">000213</idno><idno type="wicri:Area/Main/Exploration">000183</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Human immunoglobulin</term><term>Indium-111</term><term>Pneumocystis carinii pneumonia</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Sida</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Functional imaging is ideally suited to monitoring the effect of specific therapy on disease processes. In this pilot study five patients with AIDS and Pneumocystis carinii pneumonia (PCP) were imaged with Indium-111 labelled pooled human immunoglobulin (111In-HIG) during infection and after therapy for PCP. The lung activity of t t tln-HIG, measured as a lung/heart ratio, was calculated in a study performed during infection with PCP and after therapy. In all five patients the lung/heart ratio of t t 1ln-HIG was reduced after treatment. The mean reduction in heart/lung ratio was 27% (range 12%-53%). If these results are confirmed by a larger study, 11In-HIG will be useful in monitoring the response of PCP to therapy in patients with AIDS.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="237426983ae1a238a4f050f4d877db2f9a41b06b"><titleInfo lang="eng"><title>Indium-111 labelled pooled human immunoglobulin imaging to monitor the efficacy of specific therapy for Pneumocystis carinii pneumonia</title></titleInfo><name type="personal"><namePart type="given">J. R.</namePart><namePart type="family">Buscombe</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Royal Free Hospital and School of Medicine, London, UK</affiliation></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Khalkhali</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Harbor-UCLA Medical Centre, Torrance, California, USA</affiliation></name><name type="personal"><namePart type="given">G. R.</namePart><namePart type="family">Mason</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Harbor-UCLA Medical Centre, Torrance, California, USA</affiliation></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Rauh</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>R.W. Johnson Pharmaceutical Research Institute, Spring House, USA</affiliation></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Meatherall</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>R.W. Johnson Pharmaceutical Research Institute, Spring House, USA</affiliation></name><name type="personal"><namePart type="given">W. J. G.</namePart><namePart type="family">Oyen</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>University Hospital, Nijmegen, Netherlands</affiliation></name><name type="personal"><namePart type="given">F. H. M.</namePart><namePart type="family">Corstens</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>University Hospital, Nijmegen, Netherlands</affiliation></name><typeOfResource>text</typeOfResource><genre>Short Communication</genre><genre>Brief Communication</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1994-05-07</dateCreated><dateValid encoding="w3cdtf">2004-07-07</dateValid><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Functional imaging is ideally suited to monitoring the effect of specific therapy on disease processes. In this pilot study five patients with AIDS and Pneumocystis carinii pneumonia (PCP) were imaged with Indium-111 labelled pooled human immunoglobulin (111In-HIG) during infection and after therapy for PCP. The lung activity of t t tln-HIG, measured as a lung/heart ratio, was calculated in a study performed during infection with PCP and after therapy. In all five patients the lung/heart ratio of t t 1ln-HIG was reduced after treatment. The mean reduction in heart/lung ratio was 27% (range 12%-53%). If these results are confirmed by a larger study, 11In-HIG will be useful in monitoring the response of PCP to therapy in patients with AIDS.</abstract><subject lang="eng"><genre>Key words</genre><topic>AIDS</topic><topic>Pneumocystis carinii pneumonia</topic><topic>Indium-111</topic><topic>Human immunoglobulin</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1994</partNumber><partNumber>Volume: 21</partNumber><partNumber>Number: 10</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1994-10-01</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 24</identifier><recordInfo><recordOrigin>Springer-Verlag Berlin Heidelberg, 1994</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00181072</identifier><identifier type="matrixNumber">Art16</identifier><identifier type="local">BF00181072</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>1148</start><end>1150</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin><recordIdentifier>259_1994_Article_BF00181072.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000183 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000183 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1994_Article_BF00181072.pdf
|texte= Indium-111 labelled pooled human immunoglobulin imaging to monitor the efficacy of specific therapy for Pneumocystis carinii pneumonia
}}
| This area was generated with Dilib version V0.5.81. |  |